Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

immunity · Mechanism Report

Does an allergic-type pattern with elevated eosinophils and basophils reflect Type-2 activation that co-occurs with autoimmune disease?

Elevated eosinophil and basophil levels reflect Type‑2 (Th2) immune activation that frequently co-occurs with and can contribute to autoimmune disease.

SupportedJune 19, 20269 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

An allergic-type immune pattern with higher eosinophils and basophils reflects type-2 immune activation that can co-occur with autoimmune disease.

laying out figure…
1 of 2 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim states that an allergic-type immune pattern—marked by higher eosinophils and basophils—is a validated indicator of Type‑2 immune activation. Mechanistically, basophils provide early IL‑4 signals that polarize Th2 responses while IL‑5 drives eosinophil recruitment, and this Th2 cytokine environment can accompany and promote autoimmune pathology through effects like B‑cell dysregulation and tissue fibrosis.

Verified conclusion

While traditional models of immunology once viewed autoimmune and allergic responses as mutually exclusive, modern research establishes that Type-2 (Th2) immune activation frequently co-exists with and contributes to the pathology of autoimmune diseases.

Mechanistic basis of Type-2 activation

Elevated eosinophil and basophil levels serve as primary markers for Type-2 immune activation. These cells are not merely passive indicators but active drivers of the Th2 environment:

  • Basophils as Initiators: Basophils act as early initiators of the Th2 response by producing IL-4, which directs naive CD4+ T cells to differentiate into Th2 cells. They also express MHC class II and OX40 ligand, directly facilitating Th2 polarization.
  • Eosinophil Recruitment: Eosinophils are recruited and differentiated primarily by IL-5. Once present, they contribute to tissue remodeling and inflammation.
  • Synergistic Relationship: Basophils function as "gatekeepers," coordinating the recruitment of eosinophils into tissues via endothelial interactions. When basophil activation is suppressed, researchers observe a corresponding decrease in the Th2 cytokine triad (IL-4, IL-5, and IL-13) and reduced eosinophilic inflammation.

Co-occurrence in autoimmune disease

The paradigm that autoimmunity is solely driven by Th1 or Th17 pathways has been revised to include Type-2 activation across several conditions:

  • Th2-Driven Autoimmunity: Type-2 responses are central to the pathogenesis of IgG4-related disease (IgG4-RD), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and membranous nephropathy. In these cases, Th2 cytokines drive critical processes like B-cell dysregulation and fibrosis.
  • Systemic Conditions: Conditions such as systemic lupus erythematosus (SLE) and Sjögren’s syndrome are frequently characterized as $TH_2$-dominant, illustrating that allergic-type immune patterns can be a consistent feature of systemic autoimmunity.
  • Bystander Activation: Environmental triggers or microbial dysbiosis can amplify Th2 responses simultaneously with autoimmune pathology, a process known as "bystander activation."

Bottom line

An allergic-type immune pattern with higher eosinophils and basophils is a scientifically validated reflection of Type-2 immune activation. This activation is not limited to allergies but frequently co-occurs with and drives the progression of various autoimmune diseases through cytokine-mediated B-cell activation and tissue fibrosis.

References

  1. Behind the scenes with basophils: an emerging therapeutic target — academic.oup.com ↗
  2. Basophils and type 2 immunity — pmc.ncbi.nlm.nih.gov ↗
  3. Mepolizumab does not alter blood basophil count in severe asthma — publications.ersnet.org ↗
  4. Basophils Orchestrating Eosinophils’ Chemotaxis and Function in Allergic Inflammation — mdpi.com ↗
  5. Shuang-Huang-Lian Attenuates Airway Hyperresponsiveness and Inflammation in a Shrimp Protein-Induced Murine Asthma Model — hindawi.com ↗
  6. Immune Dysregulation in IgG4-Related Disease — frontiersin.org ↗
  7. POS1268 TYPE 2 (TH2) CYTOKINES AND SCLERODERMA INTERSTITIAL LUNG DISEASE (SSC-ILD) — ard.bmj.com ↗
  8. Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses — frontiersin.org ↗
  9. Type 2 hypersensitivity disorders, including systemic lupus erythematosus, Sjögren’s syndrome, Graves’ disease, myasthenia gravis, immune thrombocytopenia, autoimmune hemolytic anemia, dermatomyositis, and graft-versus-host disease, are THαβ-dominant autoimmune diseases — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible10 sourcesDoes low-normal vitamin D weaken immune resilience?→Plausible11 sourcesCan low zinc and low vitamin D constrain immune pathways while an optimal hs-CRP does not support active systemic inflammation?→